#281 ‒ Longevity drugs, aging biomarkers, and updated findings from the Interventions Testing Program (ITP) | Rich Miller, M.D., Ph.D.
“What we try to do is quite simple. We try to find drugs that will slow aging and extend mouse lifespan.” —Rich Miller
#285 – AMA #55: Exercise: longevity-focused training, goal setting, improving deficiencies, managing emotional stress, and more
“Nothing comes close to having a greater impact on the length and quality of your life than your training. And unfortunately, we can’t put it in a pill. You’ve got to be able to do it. There’s no biohack for it.” —Peter Attia
Removing race as a risk factor for cardiovascular disease?
The AHA has announced a new “race-free” assessment tool, but eliminating this variable carries the potential to increase – rather than decrease – racial disparities in healthcare
#294 ‒ Peak athletic performance: How to measure it and how to train for it from the coach of the most elite athletes on earth | Olav Aleksander Bu
Olav Aleksander Bu is an internationally renowned sports scientist acclaimed for his coaching prowess with elite athletes spanning a diverse…
#274 – Performance-enhancing drugs and hormones: risks, rewards, and broader implications for the public | Derek: More Plates, More Dates
“There’s no drug that’s purely selective exactly where you want and it’s perfect.” —Derek – More Plates More Dates
#04 – AMA #1: alcohol, best lab tests, wearables, finding the right doc, racing, and more
“I feel the need…the need for speed.” —Maverick and Goose
#240 ‒ The confusion around HDL and its link to cardiovascular disease | Dan Rader, M.D.
“HDL cholesterol itself is not directly and causally protective against atherosclerotic cardiovascular disease.” —Dan Rader